FDA Panel To Mull Risks Of Amgen’s Enbrel For Pediatric Psoriasis
Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.
Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.